- Market Realist•18 hours ago
After analysis of a Part A study of a combination of VX-661 and Ivacaftor, Vertex decided to stop the study, which included CF patients with two mutations.
- Market Realist•19 hours ago
The addressable population for Vertex Pharmaceuticals’ (VRTX) two commercialized products Kalydeco and Orkambi is currently 27,000.
Vertex Pharmaceuticals Incorporated (VRTX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||71.12 x 100|
|Day's Range||87.26 - 89.19|
|52wk Range||75.90 - 134.71|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-78.59|
|Avg Vol (3m)||1,335,200|
|Dividend & Yield||N/A (N/A)|